This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy Manufacturing & Commercialization US

Early Registration Savings Deadline Expires In

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
September 27-30, 2022Boston Convention and Exhibition Center

Akshata Ijantkar
Senior Scientist at Bristol Myers Squibb


Akshata Ijantkar is a Senior Scientist at Bristol Myers Squibb, Seattle. She is the Analytical CMC lead for Autologous and Allogenic gene-edited programs. Her areas of expertise include statistics, assay design, analytical strategy, cell, and gene therapy. She was part of the product development team that led Breyanzi from process lock, IND, INDa, BLA, and post BLA/ commercial activities. Akshata has six years of experience in cell therapy and eight years of experience in analytical development. Before joining Juno Therapeutics (later acquired by Celgene + Bristol Myers Squibb) Akshata worked as a Flow Cytometry Scientist at Pfizer, Dept of Vaccine Therapeutics.

Agenda Sessions

  • Phase Appropriate Assay Qualification and Robustness for Cell Therapy RFI (Release for Infusion) Products